BISPECIFIC ANTIBODIES THAT BIND TO COMPLEMENT PROTEINS

• US 20110002931A1
• Filed: 06/22/2010
• Published: 01/06/2011
• Est. Priority Date: 06/23/2009
• Status: Abandoned Application

• Current Assignee: Alexion Pharmaceuticals Incorporated (Astrazeneca PLC)
• Original Assignee: Alexion Pharmaceuticals Incorporated (Astrazeneca PLC)
• Inventors: Tamburini, Paul P.
• Application Number:
  US12/820,654
• Publication Number:
  US 20110002931A1
• Time in Patent Office: Days
• US Class Current: 424/136.1
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 15/06 Antiabortive agents; Labour repressants
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/94 : Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

The present disclosure relates to bispecific antibodies that can bind to two or more different epitopes. For example, the bispecific antibodies described herein can bind to two or more different proteins, wherein at least two of the proteins are selected from C5a, C5b, a cellular receptor for C5a (e.g., C5aR1 or C5L2), the C5b-9 complex, and a component or intermediate of terminal complement such as C5b-6, C5b-7, or C5b-8. The bispecific antibodies described herein are useful for, e.g., inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 complex) and/or C5a anaphylatoxin-mediated inflammation (e.g., C5a-mediated chemotaxis of inflammatory immune cells). Accordingly, the bispecific antibodies can be used in methods for treating a variety of complement pathway-associated disorders.

Claims

1. A bispecific antibody that binds to:

(a) C5a and C5aR1;

(b) C5a and C5b;

(c) C5b and C5aR1;

(d) C5a and C5L2;

(e) C5b and C5L2;

(f) C5aR1 and C5L2;

(g) C5b-6 and C5a;

(h) C5b-6 and C5b;

(i) C5b-6 and C5aR1;

or (j) C5b-6 and C5L2.

2. A bispecific antibody comprising at least two different antigen combining sites, wherein:

(i) at least one antigen combining site binds to C5a and at least one antigen combining site binds to C5b or a cellular receptor for C5a;

(ii) at least one antigen combining site binds to C5b and at least one antigen combining site binds to a cellular receptor for C5a;

(iii) at least one antigen combining site binds to C5a or C5b and at least one antigen combining site binds to a cellular receptor for C5a;

(iv) at least one antigen combining site binds to C5a, C5b, or a cellular receptor for C5a and at least one antigen combining site binds to C5b-6;

(v) at least one antigen combining site binds to C5aR1 and at least one antigen combining site binds to C5L2;

or

(vi) at least one antigen combining site binds to C5b, C5b-6, C6, C7, C8, or C9 and at least one antigen combining site binds to C5a or a cellular receptor for C5a.

3. The bispecific antibody of claim 2, wherein the bispecific antibody does not bind to full length C5.

4. The bispecific antibody of claim 2, wherein the antibody does not bind to uncomplexed C5b or to uncomplexed C6.

5. The bispecific antibody of claim 2, wherein at least one antigen combining site binds to desarginated C5a.

6. The bispecific antibody of claim 2, wherein at least one antigen combining site binds to a mammalian C5a.

7. The bispecific antibody of claim 6, wherein the mammalian C5a is human C5a.

8. The bispecific antibody of claim 6, wherein at least one antigen combining site binds to a C5a protein having an amino acid sequence that is at least 90% identical to the amino acid sequence depicted in SEQ ID NO:

1.

9. The bispecific antibody of claim 7, wherein at least one antigen combining site binds to a fragment of a human C5a protein comprising the amino acid sequence depicted in any one of SEQ ID NOs:

2-14.

10. The bispecific antibody of claim 2, wherein the cellular receptor for C5a is C5aR1.

11. The bispecific antibody of claim 10, wherein C5aR1 is human C5aR1.

12. The bispecific antibody of claim 2, wherein the cellular receptor for C5a is C5L2.

13. The bispecific antibody of claim 12, wherein C5L2 is human C5L2.

14. The bispecific antibody of claim 2, wherein at least one antigen combining site binds to C5b.

15. The bispecific antibody of claim 14, wherein C5b is human C5b.

16. The bispecific antibody of claim 15, wherein the at least one antigen combining site binds to a human C5b protein comprising an amino acid sequence that is at least 90% identical to the amino acid sequence depicted in SEQ ID NO:

15 or 16.

17. The bispecific antibody of claim 2, wherein the antibody inhibits the assembly or activity of the C5b-9 complex.

18. The bispecific antibody of claim 2, wherein the antibody inhibits C5a-dependent chemotaxis.

19. The bispecific antibody of claim 2, wherein the antibody inhibits the interaction between C5a and a cellular receptor for C5a.

20. The bispecific antibody of claim 2, wherein the antibody inhibits the interaction between C5b and C6.

21. The bispecific antibody of claim 2, wherein the antibody inhibits complement-dependent lysis in vitro.

22. The bispecific antibody of claim 2, wherein the antibody is a monoclonal antibody.

23. The bispecific antibody of claim 2, wherein the antibody is a single-chain antibody.

24. The bispecific antibody of claim 2, wherein the antibody is a humanized antibody.

25. The bispecific antibody of claim 2, wherein the antibody comprises two different monospecific antibodies that are associated with one another.

26. The bispecific antibody of claim 2, wherein the antibody is selected from the group consisting of a recombinant antibody, a diabody, an intrabody, a chimerized or chimeric antibody, a deimmunized human antibody, a fully human antibody, and an F(ab′

)₂ fragment.

27. The bispecific antibody of claim 2, wherein the antibody is a single chain diabody, a tandem single chain Fv fragment, a tandem single chain diabody, or a fusion protein comprising a single chain diabody and at least a portion of an immunoglobulin heavy chain constant region.

28. The bispecific antibody of claim 2, wherein the antibody is a dual variable domain immunoglobulin.

29. The bispecific antibody of claim 2, wherein the antibody comprises a heterologous moiety.

30. The bispecific antibody of claim 29, wherein the heterologous moiety is a sugar, a detectable label, or a stabilization moiety.

31. A pharmaceutical composition comprising the bispecific antibody of claim 2 and a pharmaceutically-acceptable carrier.

32. A method for treating a complement-associated disorder in a subject, the method comprising administering to a subject in need thereof an antibody in an amount effective to treat a complement-associated disorder in the subject, wherein the antibody is the bispecific antibody of claim 2.

33. The method of claim 32, wherein the complement-associated disorder is selected from the group consisting of rheumatoid arthritis, asthma, ischemia-reperfusion injury, atypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, paroxysmal nocturnal hemoglobinuria, dense deposit disease, age-related macular degeneration, spontaneous fetal loss, Pauci-immune vasculitis, epidermolysis bullosa, recurrent fetal loss, multiple sclerosis, traumatic brain injury, Degos'"'"' disease, myasthenia gravis, cold agglutinin disease, dermatomyositis, Graves'"'"' disease, Hashimoto'"'"'s thyroiditis, type I diabetes, psoriasis, pemphigus, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, Goodpasture syndrome, antiphospholipid syndrome, and catastrophic antiphospholipid syndrome.

34. The method of claim 32, wherein the subject is a human.